Mimedx (MDXG) Gains from Investment Securities (2017 - 2025)

Mimedx (MDXG) reported Gains from Investment Securities of $7000.0 for Q1 2025, down 99.94% sequentially from $12.2 million in Q3 2017.

Mimedx (MDXG) Gains from Investment Securities (2017 - 2025) Analysis & Trends

Mimedx (MDXG) has 2 years of Gains from Investment Securities data on file, last reported at $7000.0 in Q1 2025.

For the quarter ending Q1 2025, Gains from Investment Securities changed N/A year-over-year to $7000.0; the trailing twelve-month figure through Sep 2017 stood at $12.2 million (changed N/A YoY), and the FY2017 full-year result was -$3.6 million, down 115.76% from the prior year.
Gains from Investment Securities fell to $7000.0 in Q1 2025, from $12.2 million in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $7000.0 in Q1 2025 to a low of $7000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Mimedx	635.35 Mn	475.58 Mn	41.62 Mn

Download Data